Senator Warren Urges FTC to Scrutinize Novo Holdings' $16.5B Catalent Acquisition

The proposed merger raises antitrust concerns over Novo Nordisk's potential control in the GLP-1 drug market.

U.S. Senator Elizabeth Warren has called on the FTC to investigate Novo Nordisk's acquisition of Catalent, citing potential antitrust violations.
The $16.5 billion deal could give Novo Nordisk significant control over the production of GLP-1 drugs, crucial for obesity and diabetes treatment.
Critics, including Eli Lilly, highlight concerns about Novo Nordisk's potential access to competitors' production data and capacity.
The FTC has previously warned Novo Nordisk over patent issues, adding to concerns about anti-competitive practices.
The pharmaceutical industry's consolidation trend could lead to fewer dominant firms and higher drug prices, intensifying scrutiny of such mergers.